NervGen Pharma Corp
XTSX:NGEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
NervGen Pharma Corp
XTSX:NGEN
|
CA |
|
Steel Connect Inc
NASDAQ:STCN
|
US |
|
Halcyon Agri Corporation Ltd
SGX:5VJ
|
SG |
|
L
|
Lion Rock Resources Inc
XTSX:ROAR
|
CA |
|
D
|
Dhunseri Ventures Ltd
NSE:DVL
|
IN |
|
H
|
HB Technology Co Ltd
KOSDAQ:078150
|
KR |
|
Z
|
Zamet SA
WSE:ZMT
|
PL |
|
C
|
ChipMOS Technologies Inc
TWSE:8150
|
TW |
|
Asia Vital Components Co Ltd
TWSE:3017
|
TW |
|
Ssangyong Motor Co Ltd
KRX:003620
|
KR |
|
S
|
Steakholder Foods Ltd
NASDAQ:STKH
|
IL |
|
N
|
NHN Bugs Corp
KOSDAQ:104200
|
KR |
|
Cambridge Technology Enterprises Ltd
NSE:CTE
|
IN |
|
Yatas Yatak ve Yorgan Sanayi Ticaret AS
IST:YATAS.E
|
TR |
|
D
|
DevPort AB
STO:DEVP B
|
SE |
|
Radius Residential Care Ltd
NZX:RAD
|
NZ |
|
Colefax Group PLC
LSE:CFX
|
UK |
|
S
|
Sparebank 1 Nordmore
OSE:SNOR
|
NO |
|
American Graphite Technologies Inc
OTC:AGIN
|
US |
|
S
|
Servicios Corporativos Javer SAB de CV
BMV:JAVER
|
MX |
NervGen Pharma Corp
NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of nervous system injury due to trauma or disease as a result of underlying inflammation and/or neurodegeneration. The firm is advancing its lead compound, NVG-291, which is for the treatment of multiple sclerosis (MS), spinal cord injury (SCI) and Alzheimer’s disease. The firm has two wholly owned subsidiaries are NervGen US Inc. and NervGen Australia Pty Ltd.
NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of nervous system injury due to trauma or disease as a result of underlying inflammation and/or neurodegeneration. The firm is advancing its lead compound, NVG-291, which is for the treatment of multiple sclerosis (MS), spinal cord injury (SCI) and Alzheimer’s disease. The firm has two wholly owned subsidiaries are NervGen US Inc. and NervGen Australia Pty Ltd.
